Company news
Erasca, Inc. (NASDAQ:ERAS) news
Erasca, Inc. news releases on 6ix. Latest, Sep 10, 2026: Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Press releases & updates
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
September 10, 2026
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 8, 2026
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
August 24, 2026
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
August 11, 2026
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2026
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
July 13, 2026
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
July 13, 2026
Erasca to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Erasca Reports First Quarter 2026 Business Updates and Financial Results
May 11, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
April 27, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
March 12, 2026
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
March 9, 2026
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
March 4, 2026
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
February 23, 2026
Erasca to Present at Upcoming Conferences in February
February 4, 2026
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 23, 2026
Erasca Announces Pricing of Upsized Public Offering of Common Stock
January 20, 2026
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
January 20, 2026
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
January 11, 2026
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Erasca to Present at the 8th Annual Evercore Healthcare Conference
November 24, 2025
Erasca Reports Third Quarter 2025 Business Updates and Financial Results
November 11, 2025
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015
November 5, 2025
Erasca to Present at Upcoming Conferences in November
November 3, 2025
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 1, 2025
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
August 11, 2025
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
June 1, 2025
Erasca to Present at Upcoming Investor Conferences in June
May 28, 2025
Erasca Reports First Quarter 2025 Business Updates and Financial Results
May 12, 2025
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
May 12, 2025
Erasca to Present at the Bank of America Securities Health Care Conference
May 6, 2025
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
April 28, 2025
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
March 24, 2025
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
March 19, 2025
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
January 30, 2025
Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
November 11, 2024
Erasca to Present at Upcoming Investor Conferences
November 4, 2024
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
October 23, 2024
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
September 24, 2024
Erasca to Present at Upcoming Investor Conferences in September
August 28, 2024
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
August 11, 2024
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
June 17, 2024
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
May 20, 2024
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
May 15, 2024
Erasca Announces Pricing of Underwritten Offering of Common Stock
May 15, 2024
Erasca Reports First Quarter 2024 Business Updates and Financial Results
May 7, 2024
Erasca to Present at the Bank of America Health Care Conference
May 6, 2024
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
April 23, 2024
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
March 26, 2024